Jafron Biomedical Financials
| 300529 Stock | 26.15 0.10 0.38% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 528.6 M | 601.6 M |
|
|
Jafron | Select Account or Indicator |
Understanding current and past Jafron Biomedical Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Jafron Biomedical's financial statements are interrelated, with each one affecting the others. For example, an increase in Jafron Biomedical's assets may result in an increase in income on the income statement.
Please note, the presentation of Jafron Biomedical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Jafron Biomedical's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Jafron Biomedical's management manipulating its earnings.
Jafron Biomedical Stock Summary
Jafron Biomedical competes with Haima Automobile, Zhongshan Public, Hunan Investment, CIMC Vehicles, and Xiamen Insight. Jafron Biomedical is entity of China. It is traded as Stock on SHE exchange.Specialization | Health Care, Health Care Equipment & Services |
| Instrument | China Stock View All |
| Exchange | Shenzhen Stock Exchange |
| ISIN | CNE100002995 |
| Business Address | No 98 Technology |
| Sector | Health Care Equipment & Supplies |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.jafroninternational.com |
| Phone | 86 75 6368 9708 |
You should never invest in Jafron Biomedical without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Jafron Stock, because this is throwing your money away. Analyzing the key information contained in Jafron Biomedical's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Jafron Biomedical Key Financial Ratios
Jafron Biomedical's financial ratios allow both analysts and investors to convert raw data from Jafron Biomedical's financial statements into concise, actionable information that can be used to evaluate the performance of Jafron Biomedical over time and compare it to other companies across industries.| Revenue | 1.92 B | ||||
| Gross Profit | 2.12 B | ||||
| EBITDA | 1.04 B | ||||
| Net Income | 436.49 M | ||||
| Total Asset | 5.54 B |
Jafron Biomedical Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 3.2B | 4.8B | 5.4B | 5.5B | 6.4B | 6.7B | |
| Other Current Liab | 140.8M | 129.3M | 5.5M | 4.9M | 5.6M | 5.3M | |
| Other Liab | 51.1M | 61.5M | 52.2M | 125.8M | 144.7M | 151.9M | |
| Retained Earnings | 1.7B | 2.3B | 2.1B | 2.0B | 2.3B | 2.4B | |
| Accounts Payable | 50.2M | 60.8M | 128.5M | 135.6M | 156.0M | 163.8M | |
| Cash | 1.6B | 2.3B | 2.6B | 2.8B | 3.2B | 3.4B | |
| Other Assets | 107.9M | 102.4M | 91.6M | 225.4M | 259.2M | 272.2M | |
| Net Receivables | 167.4M | 269.1M | 221.7M | 74.9M | 86.1M | 115.1M | |
| Inventory | 120.7M | 196.5M | 349.1M | 385.0M | 442.7M | 464.9M | |
| Other Current Assets | 65.3M | 75.3M | 35.6M | 17.3M | 19.8M | 26.1M | |
| Total Liab | 383.1M | 1.4B | 1.8B | 2.4B | 2.7B | 2.9B | |
| Intangible Assets | 89.9M | 101.3M | 100.4M | 100.4M | 115.4M | 121.2M | |
| Common Stock | 417.3M | 418.7M | 799.1M | 805.5M | 926.3M | 972.6M | |
| Net Tangible Assets | 1.6B | 2.1B | 2.7B | 3.2B | 3.7B | 2.0B | |
| Total Current Assets | 2.0B | 3.1B | 3.3B | 3.3B | 3.8B | 2.1B | |
| Net Invested Capital | 2.8B | 4.3B | 4.8B | 4.8B | 5.5B | 3.4B | |
| Net Working Capital | 1.7B | 2.7B | 2.6B | 2.5B | 2.9B | 2.0B | |
| Capital Stock | 799.1M | 805.5M | 807.7M | 807.6M | 928.7M | 743.6M |
Jafron Biomedical Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Revenue | 2.0B | 2.7B | 2.5B | 1.9B | 2.2B | 1.2B | |
| Operating Income | 1.0B | 1.4B | 1.0B | 523.2M | 601.6M | 528.6M | |
| Research Development | 80.8M | 173.8M | 253.9M | 245.4M | 282.2M | 296.3M | |
| Cost Of Revenue | 288.0M | 402.1M | 440.1M | 384.0M | 441.6M | 463.7M | |
| Income Before Tax | 1.0B | 1.4B | 1.0B | 521.0M | 599.2M | 549.8M | |
| Income Tax Expense | 72.2M | 102.6M | 159.0M | 211.4M | 243.1M | 255.2M | |
| Gross Profit | 1.7B | 2.3B | 2.1B | 1.5B | 1.8B | 1.4B | |
| Ebit | 409.4M | 604.5M | 965.5M | 1.3B | 1.5B | 1.6B | |
| Net Income | 875.2M | 1.2B | 889.6M | 436.5M | 502.0M | 618.2M | |
| Minority Interest | 26.8M | 971.9K | 8.6M | 10.8M | 12.4M | 12.2M | |
| Tax Provision | 159.0M | 211.4M | 135.9M | 95.3M | 109.6M | 119.8M | |
| Net Interest Income | 27.5M | 13.2M | 16.7M | 32.7M | 37.6M | 39.5M | |
| Interest Income | 28.8M | 27.8M | 53.3M | 88.0M | 101.2M | 106.2M | |
| Ebitda | 701.1M | 1.1B | 1.5B | 1.1B | 1.3B | 944.9M |
Jafron Biomedical Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Jafron Biomedical. It measures of how well Jafron is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Jafron Biomedical brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Jafron had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Jafron Biomedical has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Dividends Paid | 377.8M | 531.0M | 729.4M | 561.8M | 646.1M | 678.4M | |
| Capital Expenditures | 357.1M | 537.4M | 475.9M | 247.3M | 284.3M | 209.4M | |
| Change To Inventory | (28.3M) | (75.9M) | (152.7M) | (37.3M) | (33.6M) | (35.2M) | |
| Change In Cash | 303.3M | 744.4M | 211.9M | 215.2M | 247.5M | 306.6M | |
| Depreciation | 36.7M | 52.6M | 74.0M | 94.8M | 109.0M | 114.5M | |
| Net Income | 875.2M | 1.2B | 889.5M | 436.5M | 502.0M | 618.2M | |
| Change To Netincome | (37.9M) | (33.5M) | (15.0M) | (14.1M) | (12.7M) | (13.3M) | |
| End Period Cash Flow | 1.6B | 2.3B | 2.5B | 2.7B | 3.2B | 1.8B | |
| Free Cash Flow | 600.4M | 712.0M | 407.9M | 669.5M | 769.9M | 485.5M | |
| Other Non Cash Items | 2.2M | 13.6M | 44.7M | 72.5M | 83.4M | 87.6M |
Jafron Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Jafron Biomedical's current stock value. Our valuation model uses many indicators to compare Jafron Biomedical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Jafron Biomedical competition to find correlations between indicators driving Jafron Biomedical's intrinsic value. More Info.Jafron Biomedical Co is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.42 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Jafron Biomedical Co is roughly 2.35 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Jafron Biomedical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Jafron Biomedical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Jafron Biomedical Systematic Risk
Jafron Biomedical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Jafron Biomedical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Jafron Biomedical correlated with the market. If Beta is less than 0 Jafron Biomedical generally moves in the opposite direction as compared to the market. If Jafron Biomedical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Jafron Biomedical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Jafron Biomedical is generally in the same direction as the market. If Beta > 1 Jafron Biomedical moves generally in the same direction as, but more than the movement of the benchmark.
Jafron Biomedical Co Total Assets Over Time
Jafron Biomedical Thematic Clasifications
Jafron Biomedical Co is part of Drugs investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery
This theme covers Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. Get More Thematic Ideas
| Drugs | View |
Jafron Biomedical March 25, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Jafron Biomedical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Jafron Biomedical Co. We use our internally-developed statistical techniques to arrive at the intrinsic value of Jafron Biomedical Co based on widely used predictive technical indicators. In general, we focus on analyzing Jafron Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Jafron Biomedical's daily price indicators and compare them against related drivers.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 11.86 | |||
| Value At Risk | (2.27) | |||
| Potential Upside | 1.9 |
Complementary Tools for Jafron Stock analysis
When running Jafron Biomedical's price analysis, check to measure Jafron Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jafron Biomedical is operating at the current time. Most of Jafron Biomedical's value examination focuses on studying past and present price action to predict the probability of Jafron Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jafron Biomedical's price. Additionally, you may evaluate how the addition of Jafron Biomedical to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |